Global Dilated Cardiomyopathy Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado de la miocardiopatía dilatada

Se espera que el mercado mundial de miocardiopatía dilatada experimente un crecimiento significativo durante el período de pronóstico. Hubo alrededor de 2,5 millones de casos prevalentes de miocardiopatía dilatada. Según el Registro de Miocardiopatía Pediátrica, la miocardiopatía dilatada se presenta a una tasa de 6 por millón de niños. Por lo general, se diagnostica en niños más pequeños con una edad promedio de diagnóstico de 2 años. Los síntomas comunes incluyen fatiga, edema en tobillos, pies, piernas, venas en el cuello y abdomen. COVID-19 también tuvo un impacto importante en el crecimiento del mercado.

Data Bridge Market Research analiza la tasa de crecimiento del mercado mundial de miocardiopatía dilatada en el período de pronóstico 2022-2029. La CAGR esperada del mercado mundial de miocardiopatía dilatada tiende a rondar el 4% en el período de pronóstico mencionado. El mercado se valoró en USD 328,8 millones en 2021 y crecería hasta USD 450 millones en 2029. El mercado mundial de miocardiopatía dilatada tiende a tener una CAGR saludable en el período de pronóstico mencionado. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

La miocardiopatía dilatada es un término que se da a las enfermedades del músculo cardíaco y se considera un trastorno cardíaco mortal. Por lo general, se caracteriza por la dilatación de los ventrículos izquierdo y derecho y la reducción de la contractilidad miocárdica. Una causa común de insuficiencia cardíaca es la incompetencia del corazón para suministrar al cuerpo suficiente sangre, y la miocardiopatía dilatada también contribuye a factores como latidos cardíacos irregulares, coágulos de sangre o muerte súbita. La miocardiopatía dilatada afecta a personas de todos los grupos de edad, que incluyen bebés y niños, pero es más común en hombres de entre 20 y 50 años. Esta enfermedad está aumentando y, por lo tanto, es muy importante para el sector de la atención médica.

Alcance y segmentación del mercado de la miocardiopatía dilatada

Dinámica del mercado mundial de la miocardiopatía dilatada

Conductores

• Aumento de pruebas diagnósticas

Las diferentes pruebas diagnósticas utilizadas para tratar la miocardiopatía periparto están impulsando el crecimiento del mercado. Múltiples pruebas, como la electrocardiografía y la resonancia magnética cardíaca, detectan la presencia de defectos específicos. Por lo tanto, actúa como un importante impulsor del crecimiento del mercado.

• Aumento de la prevalencia de la cardiopatía isquémica

Según las estadísticas de la OMS para el año 2020, la cardiopatía isquémica representa el 16 % de todas las muertes a nivel mundial. Según el artículo de febrero de 2020 titulado "Insuficiencia cardíaca (IC) en Francia: manejo terapéutico de la insuficiencia cardíaca crónica y riesgo de descompensación cardíaca en un entorno de la vida real", aproximadamente 1 millón de personas en Francia se verían afectadas por insuficiencia cardíaca. A pesar de un manejo terapéutico bien definido, hay aproximadamente 70 000 muertes relacionadas con la insuficiencia cardíaca y más de 150 000 hospitalizaciones. Esto impulsa el crecimiento del mercado.

Oportunidades

• Aumento del tabaquismo y cambios en el estilo de vida

Fumar cigarrillos es una de las principales causas de enfermedades y muertes evitables en los EE. UU. Es responsable de más de 480.000 muertes cada año. Además de esto, los cambios en el estilo de vida que se producen en la población actual, como un estilo de vida poco saludable, una mala alimentación, el estrés y muchos otros factores en conjunto contribuyen al desarrollo de oportunidades en el mercado.

• Aumento del número de actividades de investigación y desarrollo       

The market's growth is boosted by an increase in the number of R&D activities. This will provide beneficial opportunities for the global dilated cardiomyopathy market. To motivate researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial for the treatment of patients suffering from dilated cardiomyopathy due to a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for treating patients affected by dilated cardiomyopathy.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could limit the growth of the global dilated cardiomyopathy market over a forecast period.

• High Cost

The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This global dilated cardiomyopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global peripartum cardiomyopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Dilated Cardiomyopathy Market

 COVID-19 has left a major global public health crisis that has impacted practically every market sector. Its long-term consequences are expected to boost the industry growth during the forecast period.

The load on healthcare facilities and professionals was increasing with the rapid surge in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the dilated cardiomyopathy market. The pandemic has put a strain on the treatment procedures in general. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.

Recent Developments:

• In August 2019, MyoKardia, Inc., launched the 2nd Annual Myoseeds Research Grant Program to promote independent biology research and understand the mechanism of cardiomyopathies and its associated treatment.
• In 2019, the DCM Foundation in Ohio announced the launch of a website to raise awareness for dilated cardiomyopathy (DCM) and educate the patients to manage the heart condition. Many causes of DCM have been reported and around 1 in 250 people have DCM. Most of the patients have been reported to suffer from Idiopathic DCM. Therefore, genetic factors are considered to play a major role in idiopathic DCM. Henceforth, in order to find this relation, DCM foundation has collaborated with DCM Research Project which is funded by National Institute of Health (NIH).

Global Dilated Cardiomyopathy Market Scope

The global peripartum cardiomyopathy market is segmented on the basis of drug class, treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug class

• Angiotensin-converting enzyme (ACE) Inhibitors
• Beta-blockers
• Aldosterone antagonists,
• Angiotensin II Receptor Blockers
• Others

Treatment Type

• Medication
• Implantable Devices
• Heart Pumps
• Cardioverter-Defibrillators
• Others

Route of Administrtaion

• Oral
• Parenteral
• Others

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Dilated Cardiomyopathy Market Regional Analysis/Insights

The global dilated cardiomyopathy market is analysed and market size insights and trends are provided by diagnosis, distribution channel and end-user as referenced above.

The major countries covered in the global dilated cardiomyopathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period due to the global leaders in research and development activities, high incidence of heart diseases and the presence of refined medical facilities.

Asia-Pacific is expected to grow during the forecast period due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Dilated Cardiomyopathy Market Share Analysis

The global dilated cardiomyopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dilated cardiomyopathy market

Key players operating in the global dilated cardiomyopathy market include:

• Alexion Pharmaceuticals, Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Vertex Pharmaceuticals Incorporated (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Amgen Inc. (U.S.)
• Jazz Pharmaceuticals, Inc. (U.K.)
• Pfizer Inc (U.S.)
• PerkinElmer Inc (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)

SKU-54417